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Abstracts
Gregory L. Moneta, MD, Section EditorIncidence, Clinical Characteristics, and Long-Term Prognosis of Travel-
Associated Pulmonary Embolism
Lehmann R, Suess C, Leus N, et al. Eur Heart J 2009;30:233-41.
Conclusions: Travel-associated pulmonary embolism (PE) has an ex-
cellent long-term prognosis. The risk is low and is strictly dependent on
flight distance.
Summary: Retrospective analyses of travelers arriving at Charles de
Gaulle Airport in Paris and theMadrid-Barajas Airport have determined that
distance traveled is a significant contributing risk for PE associated with air
travel (N Engl J Med 2001;345:779-83 and Arch Intern Med 2003;163:
2766-71). The incidence of PE among passengers traveling5000 km is 1.5
cases/million compared with 0.01 cases/million in those traveling 5000
km. In this article the authors sought to determine the proportion of
travel-associated PE compared with other associated causes of PE and the
long-term prognosis after affected patients. Travel-associated PE was de-
fined as that occurring 2 months of travel.
The study monitored patients with travel-related PE who were admit-
ted to the University of Frankfurt Hospital between 1997 and 2006. This
hospital serves as the primary referral center for Frankfurt International
Airport, the largest airport in Germany and third largest in Europe. Approx-
imately one-third of the passengers arriving at this airport have traveled
5000 km.
Flight distances of passengers with travel-related PE were obtained
from data from FRAPORT AG, the operating company of Frankfurt Inter-
national Airport. Between 1997 and 2006, 257 passengers with acute PE
were admitted to the Frankfurt University Hospital intensive care unit. Of
these, 62 had travel-related PE (45 flight-associated PEs; 17 other travel-
associated PEs). Patients with travel-related PE had a nonsignificantly higher
rate of initial cardiopulmonary resuscitation (4.8% vs 1.5%; P  .153) and a
higher percentage of massive PE (8% vs 3%; P .064). Mortality was similar
in both travel-related and non-travel-related PE (4.8% vs 4.1% respectively,
P  .730). Long-term outcome of travel-related PE patients was excellent
(Kaplan-Meier analysis; log-rank P  .008) vs other entities associated with
PE. Only 13% of patients with travel-related PE had no other identifiable risk
factors, including thrombophilia, 40%; neoplasm, 7%; and family history of
venous thromboembolism or recurrent thromboembolic event, 26%. Travel-
related PE was rare, with one event per 5,000,000 passengers. Flights 5000
km led to a 17-fold increase compared with shorter flights.
Comment: The main points of this study are that travel-related PE is
exceedingly rare and is vanishingly rare in shorter flights. Virtually all patients
with travel-related PE have additional risk factors for venous thromboem-
bolism. Overall, the patients do well, with no difference in hospital mortality
compared with other patients with PE, and the patients with travel-related
PE have a better long-term prognosis.
Long-term Clinical Outcome after Intramuscular Implantation of
Bone Marrow Mononuclear Cells (Therapeutic Angiogenesis by Cell
Transplantation [TACT] Trial) in Patients with Chronic Limb
Ischemia
Matoba S, Tatsumi T, Murohara T, et al. Am Heart J 2008;156:1010-8.
Conclusion: Bone marrow mononuclear cells (BMMCs) can induce
long-term improvement in limb ischemia with extension of the amputation-
free interval.
Summary: Methods of inducing angiogenesis as a treatment for
chronic limb ischemia are being actively investigated. These authors pub-
lished an earlier clinical trial (Lancet 2002;360:427-35) of therapeutic
angiogenesis using BMMCs in patients with chronic limb ischemia second-
ary to peripheral arterial disease (PAD) or thromboangiitis obliterans
(TAO). In that trial, intramuscular implantation of autologous BMMCs
resulted in improvement in transcutaneous oxygen pressure, rest pain,
ankle-brachial index, and pain-free walking time. The current study was
designed to assess long-term safety and clinical outcome after intramuscular
injection of BMMCs in ischemic limbs.
The study included 115 patients, 74 with PAD and 41 with TAO.
After BMMC implantation, patients were evaluated every week for 4
weeks and at 6, 12, 24, and 36 months. Median follow-up time was 25.3
months (range, 0.8-69 months). The 3-year overall survival rates were
80% (95% confidence interval [CI], 68%-91%) in patients with athero-
sclerotic PAD (11 of 74 died) and 100% in 41 patients with TAO. The
amputation-free rate was 60% (95% CI, 46%-74%) in the patients with
PAD and 91% (95% CI, 82%-100%) in those with TAO. The amputation-
free interval was negatively affected by the severity of rest pain and need
for bypass surgery. Significant improvements in leg pain, ulcer size, andpain-free walking distance were maintained for 2 years after follow-up.
Ankle-brachial index and transcutaneous oxygen pressure values did not
change significantly.
Comment: The stimulus for this study was the occasional sudden
death after intramuscular injection of BMMCs (Circulation 2006;114:
2679-84). This study was thus essentially a safety analysis of the patients
treated under previously approved protocols. No control patients were
identified prospectively; therefore, the authors’ conclusion that “the
safety and efficacy are not inferior to the conventional revascularization
therapies” is not really valid. Angiogenesis, however, remains an intriguing
potential therapy for chronic limb ischemia. The overall data thus far are
fairly underwhelming; however, studies like this, with some hints of
improvement in clinically relevant end points, will serve to sustain
interest in angiogenesis. Some approach—probably not one of the cur-
rent approaches—using angiogenesis at least as an adjunct in the treat-
ment of chronic limb ischemia ought to work someday.
Oral Vitamin KVersus Placebo to Correct Excessive Anticoagulation in
Patients Receiving Warfarin: A Randomized Trial
Crowther MA, Ageno W, Garcia D, et al. Ann Intern Med 2009;150:293-
300.
Conclusion: Bleeding is not reduced by low-dose vitamin K therapy in
warfarin recipients with international normalized ratios (INRs) of 4.5 to
10.0.
Summary: Bleeding risk with warfarin therapy increases when the INR
is4.5 (Chest 2008;133:160-98s). In addition, INRs outside the therapeu-
tic range can occur up to one-third to one-half of the time (Chest 2005;127:
1515-22). When patients present with an INR4.5, clinicians may elect to
treat with vitamin K therapy or just withhold warfarin treatment and allow
the INR to drift down over time.
The authors hypothesized patients with INRs 4.5 treated with vita-
min K therapy would have less bleeding complications than those in which
warfarin therapy was merely withheld until the INR returned to therapeutic
levels. They tested their hypothesis by performing a multicenter randomized
trial in nonbleeding patients with INRs of 4.5 to 10.0. Patients were
randomized to receive oral vitamin K (1.25 mg) or placebo. The primary
outcome was the frequency of all forms of bleeding during the first 90 days.
Patients’ primary care givers and those assessing outcomes were blinded to
treatment assignment. Thromboembolism and death were also monitored.
There were 335 patients assigned to oral vitamin K therapy, and 347
were analyzed. There were 369 patients randomly assigned to placebo, and
365 were analyzed. At least one bleeding complication occurred in 56
patients (15.8%) in the vitamin K group and in 60 patients (16.3%) of the
patients in the placebo group, for an absolute difference of0.5 percentage
points (95% confidence interval [CI],6.1 to 5.1 percentage points). Major
bleeding events occurred in nine patients (2.5%) of the vitamin K group and
in four patients (1.1%) of the placebo group (absolute difference, 1.5
percentage points; 95%CI,0.1 to 3.7 percentage points). Four episodes of
thromboembolism (1.1%) occurred in the vitamin K group and three
episodes (0.8%) in the placebo group (absolute difference, 0.3 percentage
points; 95% CI, 1.4 to 2.0 percentage points). One day after treatment,
INR had decreased by 2.8 in the vitamin K group and by 1.4 in the placebo
group (P  .001).
Conclusion: The data indicate that active reduction of the INR by
administration of vitamin K does not reduce bleeding episodes. The data also
indicate administration of vitamin K does not result in increased thrombo-
embolism. The results have significant implications for clinical practice. In
patients with INRs between 4.5 and 10, warfarin therapy should be withheld
and reinstituted once the INR has returned to the desired range. The data
cannot be extrapolated to patients who are bleeding or who present with
INRs10. Overall, the results of the trial should help simplify the manage-
ment of most patients treated with warfarin who present with suprathera-
peutic INR levels.
Plication as Primary Treatment of Steal Syndrome in Arteriovenous
Fistulas
Yaghoubian A, de Virgilio C. Ann Vasc Surg 2009;23:103-7.
Conclusion: Plication is a simple alternative to management of steal
syndrome after construction of an autogenous arteriovenous fistula.
Summary: There is always some steal in patients after creation of an
arteriovenous fistula for hemodialysis. Pathologic steal is uncommon but can
produce devastating complications. Overall incidence is 1% to 9%. In many
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become the preferred method to treat steal syndrome. However, this oper-
ation requires a new bypass and results in ligation of the brachial artery distal
to the fistula. Although plication of an arteriovenous fistula is a known
technique for dealing with steal syndrome, it is rarely reported. In this article,
the authors describe their technique, in a small number of patients, for
plication of arteriovenous fistulas associated with clinically significant steal.
Seven patients were treated with plication. Their symptoms included pares-
thesia, coolness, and pain in the hand and fingers. No one had ulceration. In
six of seven patients, a radial artery pulse returned with compression of the
fistula.
Plication was performed using a Satinsky clamp as a guide for the
degree of plication, with the vein narrowed by a running horizontal mattress
suture of 6-0 polypropylene. The length of vein plicated was approximately
1 cm, and the extent of plication was determined by return of a palpable
pulse at the wrist or a change from monophasic to a biphasic distal Doppler
signal. If the Doppler signal did not improve, the Satinsky clamp was
reapplied and the plication repeated, further narrowing the plicated length
of the fistula. The radial pulse returned postoperatively in six of seven
patients. Mean follow-up was 9 months. At 13 months, symptoms had
recurred in only one patient, the patient in whom the radial pulse did not
return.
Comment: Many patients with steal syndrome can be managed by
observation. The inflow vessel dilates, and symptoms may resolve within a
few days to weeks. A basic principle of surgical therapy is to perform simple
procedures that are effective in preference to more complex procedures.
DRIL procedures are effective for steal, with an 83% to 100% success rate;
however, they are major operations, and the brachial artery is ligated. This
study serves as a reminder that simple plication may be an effective treatment
for steal syndrome and should be considered as an alternative treatment for
steal before performance of a DRIL procedure.
Predictors of Prosthetic Graft Infection after Infrainguinal Bypass
Brothers TE, Robison JG, Elliott BM. J Am Coll Surg 2009;208:557-61.
Conclusion: Amputation increases the risk of infrainguinal prosthetic
graft infection, especially when amputation is performed in the early post-
operative period after infrainguinal prosthetic bypass or after failed revascu-
larization.
Summary: Prosthetic bypass is inferior to autogenous vein for infrain-
guinal arterial reconstructions. Anecdotally, many surgeons have noticed
late development of infection in prosthetic bypasses after ipsilateral above or
below knee amputation. The authors hypothesized thatmajor amputation of
the lower limb would increase susceptibility of the prosthetic graft to
infection in the ipsilateral extremity. They reviewed their patients who had
undergone prosthetic infrainguinal bypass grafting during a 12-year period.
The data were extracted from a vascular surgical registry and included
demographics, operative details, and comorbid conditions. Graft infection
was the primary outcome.
There were 141 infrainguinal bypasses using prosthetic material
during the 12-year study period, and only a small minority were placed
for claudication. Prosthetic graft infection occurred in 25 (18%). Infec-
tion occurred most frequently after major amputation (41% vs 6%; odds
ratio [OR], 12; 95% confidence interval [CI], 4.1-34). The risk of graft
infection was also increased if there was an early reoperation after the
initial grafting (70% vs 16%; OR, 11; 95% CI, 1.9-63). The highest risk
was associated with amputation 4 weeks of bypass (70% vs 32%; OR,
5.0; 95% CI, 1.1-23). Also increasing the risk of infection were graft
thrombosis (84% vs 39%; OR, 8.3; 95% CI, 2.6-26) and the presence of
gangrene (52% vs 23%; OR, 3.6; 95% CI, 1.5-8.7).
Stepwise regression analysis showed the independent predictors for
graft infection were amputation (P  .001), early reoperation (P  .002),
and absence of renal failure (P .038). Amputations performed6 months
after the initial bypass were more likely to be associated with graft infection
than those performed6months after the original bypass (52% vs 17%; OR,
5.3; 95% CI, 1.3-22).
Comment: These are startling numbers. An overall incidence of 18%
for infection of infrainguinal prosthetic grafts is very high. It implies a
high-risk patient population; and indeed, very few of the grafts were placed
for claudication alone. It can be concluded the risk of prosthetic graft
infection after amputation is sufficiently high that if the graft is occluded at
the time of the amputation, serious consideration should be given to
concomitant graft removal. The other implication of the data is that if the
patient has a significant likelihood of amputation with graft failure, the
surgeon should consider other forms of revascularization, despite their
difficulty, rather than a prosthetic graft, if possible. The best way to prevent
an infrainguinal prosthetic graft infection is to never to have placed an
infrainguinal prosthetic graft in the first place.
Rehospitalizations among Patients in the Medicare Fee-for-Service
Program
Jencks SF, Williams MV, Coleman EA. N Engl J Med 2009;360:1418-28.Conclusion: Rehospitalization among Medicare beneficiaries occurs
frequently.
Summary: Under current law, payment is available from Medicare for
most rehospitalizations. An exception is for patients rehospitalized for the
same condition24 hours after discharge fromwhich they had initially been
hospitalized. Policy changes are being considered that would create payment
incentives to reduce rates of rehospitalization. Reducing rehospitalization is
an important component of President Obama’s health care reform proposals
(Washington Post, Feb 26, 2009).
The Medicare Payment Advisory Commission (MEDPAC) has sug-
gested that hospitals receive from Centers for Medicare and Medicaid
Services a confidential report of risk-adjusted rehospitalization rates and
that these rates be published after 2 years. It has also been suggested that
hospitals with high-risk adjusted rates of rehospitalization should receive
lower average per case payments. Although reducing rehospitalizations is
clearly a potential means of reducing costs, there is actually little infor-
mation on the frequency and patterns of rehospitalization. The authors
therefore analyzed Medicare claims from 2003 and 2004 in an attempt to
describe patterns of rehospitalization and relationships of rehospitaliza-
tion to demographic characteristics of the patients and the characteristics
of the hospitals.
During the period analyzed, 1,855,702 Medicare beneficiaries were
hospitalized, of which 19.6% were rehospitalized30 days; at 90 days, 34%
had been rehospitalized. Within the first year after discharge, 68.9% of
patients who had been discharged with a medical condition and 53% who
had been discharged after surgical procedures were rehospitalized or had
died. Of patients discharged with a medical condition and who were rehos-
pitalized 30 days after discharge, 52.2% had no bill for a visit to a
physician’s office between the time of discharge and rehospitalization. After
surgical discharge, 70.5% of rehospitalizations 30 days were for a medical
condition. The average stay of rehospitalized patients was 0.6 days longer
than that of patients in the same diagnostic-related group whose most recent
hospitalization had been 6 months previously. The estimated cost to
Medicare of unplanned rehospitalizations in 2004 was $17.4 billion.
Vascular surgical patients had a 23.9% rate of rehospitalization
30 days. This comprised 1.4% of all rehospitalizations of Medicare
patients. Rehospitalization was for additional vascular surgery in 14.8%
and amputation in 5.8%. In comparison, rehospitalizations 30 days
occurred in 13.5% of patients undergoing cardiac stent procedures,
15.6% of patients undergoing major bowel surgery, and 17.9% of those
undergoing hip or femur surgeries. Overall rates of rehospitalization
were region-dependent. The lowest rates were in the Pacific Northwest
and the Intermountain West.
Comment: Rehospitalization is a huge problem. The data indicated
that the risk of rehospitalization persists over time. Additional studies will
be required to understand the relative contributions of inadequate
discharge planning, insufficient outpatient and community care, and
progression of illness to rates of rehospitalization. Vascular surgeons
should note that among the surgical groups analyzed, vascular surgery
had the highest rates of rehospitalization. This has significant implica-
tions for the relationship between vascular surgeons and their hospital
administrators should there eventually be instituted a financial penalty
for rehospitalization of surgical patients.
Treadmill Exercise and Resistance Training in Patients With Peripheral
Arterial Disease With and Without Intermittent Claudication: A Ran-
domized Controlled Trial
McDermott MM, Ades P, Guralnik JM, et al. JAMA 2009;301:165-74.
Conclusions: Supervised treadmill walking training improves quality
of life, brachial artery flow–mediated dilatation, and 6-minute walk perfor-
mance as well as treadmill walking performance in patients with peripheral
arterial disease (PAD) with and without intermittent claudication. Treadmill
training did not improve short physical performance battery scores. Lower
extremity resistance training improves quality of life, stair climbing ability,
and treadmill walking in patients with PAD with and without intermittent
claudication.
Summary: Treadmill exercise training under supervised conditions
improves walking performance in patients with PAD and intermittent clau-
dication (JAMA 1995;274:975-80). The effect of treadmill training on
patients with PAD, but who do not have symptoms of claudication, is
unknown. Also unknown is whether lower extremity resistance (strength)
training in patients with PAD provides additional benefits. Adults with PAD
have a smaller calf muscle area and diminished strength of their legs than
patients without PAD, and these muscle characteristics are associated with
greater functional impairment (J Am Geriatr Soc 2008;56:224-30).
This randomized trial was designed to address two questions. The first
was to determine whether supervised exercise training on a treadmill im-
proved functional performance in patients with PAD with and without
classic symptoms of claudication. The second was to determine whether
lower extremity strength training improved functional performance in pa-
tients with PAD with and without symptoms of claudication. Each interven-
tion group was compared with a control group. The study was performed at
